Live Breaking News & Updates on பிரியா தெவ்

Stay updated with breaking news from பிரியா தெவ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Final Phase-3 results of Covaxin show efficacy of 77.8% against Covid

Final Phase-3 results of Covaxin show efficacy of 77.8% against Covid
By
IANS
|
93 Views
Final Phase-3 results of Covaxin show efficacy of 77.8% against Covid. Image Source: IANS News
New Delhi, July 3 : Efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group.
Bharat Biotech has concluded final analysis for Covaxin efficacy from Phase 3 clinical trials.
Efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19. Safety analysis demonstrates adverse events reported were similar to placebo, with 12 per cent of subjects experiencing commonly known side effects and less than 0.5 per cent of subjects feeling serious adverse events. ....

United States , New Delhi , Priya Abraham , Krishna Ella , Indian Covaxin , Balram Bhargava , Suchitra Ella , National Institute Of Virology , National Institutes Of Health , Indian Council Of Medical Research , Department Of Health Research , National Institutes , Data Safety Monitoring Board , Bharat Biotech , Managing Director , Secretary Department , Health Research , Director General Indian Council , Medical Research , Joint Managing Director , Director National Institute , Use Listing , ஒன்றுபட்டது மாநிலங்களில் , புதியது டெல்ஹி , கிருஷ்ணா எல்லா , பால்ராம் பார்கவா ,

Covaxin Phase 3 Trial Result: 65.2% Efficacy Against Delta Variant, 77.8% Against Symptomatic COVID-19 Infection

Covaxin Phase 3 Trial Result: 65.2% Efficacy Against Delta Variant, 77.8% Against Symptomatic COVID-19 Infection
Covaxin, India s indigenous COVID-19 vaccine, has concluded its final phase 3 trials and the results are out. Read on to know all about it.
Written by Jahnavi Sarma | Published : July 3, 2021 12:19 PM IST
Bharat Biotech has announced the safety and efficacy analysis data from Phase 3 clinical trials of Covaxin, its whole virion inactivated vaccine against SARS-CoV2, developed in partnership with ICMR and NIV Pune. According to the trial result, Covaxin is well tolerated and the Data Safety Monitoring Board has not reported any safety concerns related to the it. Adverse reaction to this vaccine was lower than that seen in other COVID-19 vaccines. Interestingly, Covaxin is the first to report promising efficacy against asymptomatic infections based on qPCR testing that will help in reducing disease transmission. It must be noted here that no other licensed ....

Priya Abraham , National Institute Of Virology , Covaxin Phase , Efficacy Against Delta Variant , Against Symptomatic , Data Safety Monitoring Board , Director National Institute , Bharat Biotech , Use Listing , தேசிய நிறுவனம் ஆஃப் வைராலஜி , தகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகை , இயக்குனர் தேசிய நிறுவனம் , பாரத் பயோடெக் , பயன்பாடு பட்டியல் ,

Bharat Biotech Concludes Final Analysis for COVAXIN® Efficacy from Phase 3 Clinical Trials

Bharat Biotech Concludes Final Analysis for COVAXIN® Efficacy from Phase 3 Clinical Trials
indiaeducationdiary.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiaeducationdiary.in Daily Mail and Mail on Sunday newspapers.

Andhra Pradesh , United States , Priya Abraham , Krishna Ella , Suchitra Ella , Balram Bhargava , National Institute Of Virology , Indian Council Of Medical Research , National Institutes Of Health United States , Adjudication Committee , Department Of Health Research , Bharat Biotech , National Institutes , Health United , Data Safety Monitoring Board , Managing Director , Secretary Department , Health Research , Director General Indian Council , Medical Research , Joint Managing Director , Principle Investigators , Director National Institute , Use Listing , ஆந்திரா பிரதேஷ் , ஒன்றுபட்டது மாநிலங்களில் ,

COVID-19 Updates: More Than 40K New Cases, 12 Deaths In Assam Hospital, Covaxin Booster Dose

COVID-19 Updates: More Than 40K New Cases, 12 Deaths In Assam Hospital, Covaxin Booster Dose
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.

Uttar Pradesh , Priya Abraham , Keshab Mahanta , Torrent Pharmaceuticals , Sun Pharmaceutical Industries , Emcure Pharmaceuticals , Merck Co , Indian Medical Association On , Gauhati Medical College Hospital , Pune National Institute Of Virology , National Institute , Coronavirus Treatment , Coronavirus Vaccine , Indian Medical Association , க Au ஹாட்டி , உத்தர் பிரதேஷ் , கேஷாப் மகாந்தா , நீரோடை மருந்துகள் , சூரியன் மருந்து தொழில்கள் , மெர்க் இணை , இந்தியன் மருத்துவ சங்கம் ஆன் , க Au ஹாட்டி மருத்துவ கல்லூரி மருத்துவமனை , புனே தேசிய நிறுவனம் ஆஃப் வைராலஜி , தேசிய நிறுவனம் , இந்தியன் மருத்துவ சங்கம் ,

Covaxin is effective against Delta variant says National Institutes of Health

Covaxin is effective against Delta variant says National Institutes of Health
sandesh.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandesh.com Daily Mail and Mail on Sunday newspapers.

United States , Priya Abraham , Alphae Delta , Maharashtraa National , Indian Medical Research , Science Magazine , Delta India , Director Priya Abraham , ஒன்றுபட்டது மாநிலங்களில் , இந்தியன் மருத்துவ ஆராய்ச்சி , அறிவியல் பத்திரிகை , டெல்டா இந்தியா ,